ライフサイエンスコーパス: pharmacodynamics

1 gnitude and duration of response to therapy (pharmacodynamics).

2 in part B (to assess safety and longer-term pharmacodynamics).

3 d an overall response, pharmacokinetics, and pharmacodynamics.

4 t of imaging biomarkers to monitor metabolic pharmacodynamics.

5 orbidities, and altered pharmacokinetics and pharmacodynamics.

6 ing behaviour, indicating dose dependency of pharmacodynamics.

7 itaxel release (extent and rate) and in vivo pharmacodynamics.

8 iability in clopidogrel pharmacokinetics and pharmacodynamics.

9 for understanding their pharmacokinetics and pharmacodynamics.

10 le of ABCB1 gene in SRL pharmacokinetics and pharmacodynamics.

11 ore a critical step in the prediction of its pharmacodynamics.

12 y and optimizing antibiotic pharmacokinetics/pharmacodynamics.

13 th antileukemic drug pharmacokinetics and/or pharmacodynamics.

14 owever, this increases the complexity of the pharmacodynamics.

15 ion of the conditions governing the observed pharmacodynamics.

16 micronutrients on drug pharmacokinetics and pharmacodynamics.

17 ule biodistribution, target interactions and pharmacodynamics.

18 nfirm efficacy and further define safety and pharmacodynamics.

19 both intended and unintended, that comprise pharmacodynamics.

20 iable means for quantification of paclitaxel pharmacodynamics.

21 oth maternal-fetal drug pharmacokinetics and pharmacodynamics.

22 icacy; and 18 (34%), pharmacokinetics and/or pharmacodynamics.

23 es a robust mechanism for modulating insulin pharmacodynamics.

24 exosomes to intercellular drug transfer and pharmacodynamics.

25 eir assembly, stability, immunogenicity, and pharmacodynamics.

26 acokinetic profile for assessment of in vivo pharmacodynamics.

27 c disturbance per se is unrelated to altered pharmacodynamics.

28 se is related to altered pharmacokinetics or pharmacodynamics.

29 acology of AMG 416 showed readily reversible pharmacodynamics.

30 unds impacting on their pharmacokinetics and pharmacodynamics.

31 ed pharmacokinetics, antitumor activity, and pharmacodynamics.

32 0%), efficacy (45%), pharmacokinetics (28%), pharmacodynamics (23%), and patient enrichment (14%) wer

33 were evaluable for both pharmacokinetics and pharmacodynamics (50%).

34 dual variation in anastrozole metabolism and pharmacodynamics among patients treated with the approve

35 Differences in pharmacokinetics and pharmacodynamics among statins lead to diverse biologica

36 ood, Sehgal et al report on the clinical and pharmacodynamics analysis of pomalidomide dosing strateg

37 study was to evaluate the pharmacokinetics, pharmacodynamics and anti-tumour efficacy of the first s

38 murine model that can be used to analyze the pharmacodynamics and antitumor properties of immunostimu

39 evaluates the safety, pharmacokinetics, and pharmacodynamics and defines the recommended phase II do

40 traightforward to relate pharmacokinetics to pharmacodynamics and efficacy by following the time abov

41 riteria for Adverse Events version 4.03, and pharmacodynamics and immunogenicity were also evaluated.

42 ontribute to interactions between cell-based pharmacodynamics and in vivo pharmacokinetics that defin

43 n, FQ plasma and tissue pharmacokinetics and pharmacodynamics and is based on extensive in vitro and

44 d multiple drug interactions that affect its pharmacodynamics and metabolism.

45 Assessment of safety, pharmacodynamics and nasal allergic reactivity following

46 tanding of remifentanil pharmacokinetics and pharmacodynamics and on newly proposed clinical applicat

47 t, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supp

48 ns, and fail to fully capture cytotoxic drug pharmacodynamics and pharmacokinetic variability in obes

49 We evaluated whether PEG-IFN pharmacodynamics and pharmacokinetics account for differ

50 that polymorphisms in genes affecting statin pharmacodynamics and pharmacokinetics are associated wit

51 nd neurodevelopmental delay; however, animal pharmacodynamics and pharmacokinetics do not directly co

52 We explored the pharmacodynamics and pharmacokinetics in a rabbit model.

53 However, improvement of the drug's pharmacodynamics and pharmacokinetics is desirable.

54 ted a dose-ranging study to characterize the pharmacodynamics and pharmacokinetics of eptifibatide un

55 ate the role of ECMO, including studying the pharmacodynamics and pharmacokinetics of patients receiv

56 , however, little in-depth discussion of the pharmacodynamics and pharmacokinetics of the sedation ag

57 , we examined whether genes important in the pharmacodynamics and pharmacokinetics of these drugs and

58 al drawbacks with such peptides include poor pharmacodynamics and potential scrambling of the disulfi

59 y on pathophysiology, and the alterations in pharmacodynamics and treatment.

60 ion half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with b

61 evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of AMG 386 in a

62 ssed safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of ARN-509 in m

63 and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398,

64 tives were to evaluate the pharmacokinetics, pharmacodynamics, and clinical antitumor activity of var

65 luded safety, tolerability, pharmacokinetics/pharmacodynamics, and efficacy (Disease Activity Score i

66 rial, we evaluated the safety, tolerability, pharmacodynamics, and efficacy of lumacaftor/ivacaftor c

67 uate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LY2439821, a humanized

68 rial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of selinexor (KPT-330), a

69 o characterize the safety, pharmacokinetics, pharmacodynamics, and efficacy, and to identify the reco

70 CV viral kinetics, IFN pharmacokinetics, IFN pharmacodynamics, and gene expression profiles.

71 , as well as the toxicity, pharmacokinetics, pharmacodynamics, and immunogenicity of ABX-EGF, were as

72 to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates.

73 cidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response rate.

74 o inform on different drug pharmacokinetics, pharmacodynamics, and pharmacogenetics in view of the ab

75 This study examined the safety, pharmacodynamics, and pharmacokinetics of multiple doses

76 dy to evaluate the safety, pharmacokinetics, pharmacodynamics, and potency of i.v. administrations in

77 imum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of

78 imum-tolerated dose, pharmacokinetics (PKs), pharmacodynamics, and preliminary antitumor efficacy wer

79 y tolerated regimen (OTR), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of l

80 were safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity.

81 ing drug pharmacokinetics, measuring therapy pharmacodynamics, and providing a marker of therapeutic

82 We determined the safety, pharmacokinetics, pharmacodynamics, and recommended phase II dose of MK-87

83 and to assess its safety, pharmacokinetics, pharmacodynamics, and response rate in individuals with

84 therapy, we evaluated the pharmacokinetics, pharmacodynamics, and safety profile of DX-9065a, a nove

85 arameters in understanding pharmacokinetics, pharmacodynamics, and toxicities of drugs, but these par

86 tudies of biodistribution, pharmacokinetics, pharmacodynamics, and toxicity as well as scale-up manuf

87 To investigate BBB penetration, pharmacodynamics, and tumor retention kinetics of an ago

88 were to evaluate toxicity, pharmacokinetics, pharmacodynamics, and UGT1A1 genotype.

89 ted, had dose-dependent pharmacokinetics and pharmacodynamics, and was associated with antitumor acti

90 ndence, during physiologic activity, blocker pharmacodynamics are largely indistinguishable and large

91 Carboplatin had no effect on bortezomib pharmacodynamics as measured by percent inhibition of th

92 Pharmacokinetics and pharmacodynamics assessment indicated that the degree of

93 se of physiologically based pharmacokinetic /pharmacodynamics-based approaches to forward and reverse

94 acokinetics (ABCG2, AHR, POR and CYP1A2) and pharmacodynamics (BDNF and SLC6A4) of caffeine.

95 employ conservative designs that incorporate pharmacodynamics/biomarker monitoring.

96 Sex differences in pharmacokinetics and pharmacodynamics characterize many drugs and contribute

97 Our aim was to examine pharmacodynamics (colonic transit, bowel function) and p

98 published data on tyrosine aminotransferase pharmacodynamics.Conclusions: The semi-parametric approa

99 Pharmacokinetics, pharmacodynamics, continuous electrocardiography, and cl

100 iable biochemical read out of steroidal drug pharmacodynamics could enable a rapid and objective asse

101 The pharmacokinetics/pharmacodynamics data were used to identify model parame

102 24h or continuously worn for 4 days, and the pharmacodynamics effect of changes in the intraocular pr

103 ible with live, primary cells and can report pharmacodynamics for drug action on an intended target,

104 latin alone in cycle 1 to establish baseline pharmacodynamics for nuclear factor-kappa B (NF-kB).

105 ors sought to study the pharmacokinetics and pharmacodynamics for ticagrelor 60 mg compared with 90 m

106 cokinetics, lung tissue pharmacokinetics and pharmacodynamics for two first line anti-TB antibiotics.

107 Indications of CPT pharmacodynamics from tumor biomarkers such as carbonic

108 Pharmacokinetics and pharmacodynamics guided drug dose selection for antitumo

109 ogs, pharmacokinetics in normal rabbits, and pharmacodynamics in a canine model of aqueous tear defic

110 quantification of antibody accumulation and pharmacodynamics in brain tumors, offering a holistic ap

111 ing alterations in drug pharmacokinetics and pharmacodynamics in intensive care unit patients.

112 human insulin that exhibits near-ideal basal pharmacodynamics in somatostatin-treated beagle dogs.

113 We examined pharmacodynamics in the tg2576 APPtg mouse with the prio

114 CAS demonstrates concentration-dependent pharmacodynamics in the treatment of IPA.

115 showed because of a better pharmacokinetics/pharmacodynamics index.

116 However, pharmacodynamics indicated a sustained mean occupancy of

117 d uptake of siRNA into the cell and improved pharmacodynamics inside the cell.

118 vel time-series study of drug effects (i.e., pharmacodynamics) is critical for understanding mechanis

119 Despite indistinguishable synaptic pharmacodynamics, ketamine provided significantly greate

120 en to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD), and clin

121 The computational pharmacokinetics/pharmacodynamics model can be generalized to predict who

122 gically based computational pharmacokinetics/pharmacodynamics model was constructed to simulate the r

123 e-dose adjustment protocols, pharmacokinetic/pharmacodynamics modeling and international normalizatio

124 Dose-response curves followed exponential pharmacodynamics models for calcium chloride (EC50 1.8 m

125 sex-related differences in opioid (morphine) pharmacodynamics, morphine metabolites, the nociceptin/o

126 risk for suboptimal drug concentrations and pharmacodynamics must be considered.

127 information is available on the antiplatelet pharmacodynamics of a 300-mg versus a 600-mg clopidogrel

128 he pharmacokinetics, mechanism of action and pharmacodynamics of a drug, and that select subgroups of

129 This study aims to describe the pharmacodynamics of a fluid challenge over a 10-minute p

130 therapy, however, is limited by the unknown pharmacodynamics of a replicating agent, as well as the

131 s approach allows noninvasive imaging of the pharmacodynamics of a targeted drug and will facilitate

132 significant role in the pharmacokinetics and pharmacodynamics of a variety of drugs.

133 PET will be useful for the study of in vivo pharmacodynamics of Abl PKI molecular therapy in humans.

134 the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.

135 on should center on the pharmacokinetics and pharmacodynamics of agents in an attempt to ameliorate p

136 nique insights into the pharmacokinetics and pharmacodynamics of agents that modulate Akt activity, r

137 nique insights into the pharmacokinetics and pharmacodynamics of agents that modulate c-Met activity

138 ide unique insight into pharmacokinetics and pharmacodynamics of agents that modulate EGFR activity,

139 d to 16 polymorphisms in genes linked to the pharmacodynamics of ALL chemotherapy, adjusting for age,

140 trate that both ATP7A and ATP7B modulate the pharmacodynamics of all three clinically used platinum d

141 evaluated the safety, pharmacokinetics, and pharmacodynamics of AMG 706 in patients with refractory

142 itro characterization, pharmacokinetics, and pharmacodynamics of an orally bioavailable, potent, smal

143 factors that affect the pharmacokinetics and pharmacodynamics of anesthetic agents in the obese popul

144 isms in genes related to pharmacokinetics or pharmacodynamics of antileukemic agents, drug metabolism

145 ed to 16 genetic polymorphisms affecting the pharmacodynamics of antileukemic agents.

146 nes likely to affect the pharmacokinetics or pharmacodynamics of antileukemic medications in 64 child

147 Pharmacokinetics/pharmacodynamics of antimicrobial agents, differences am

148 nificant impacts on the pharmacokinetics and pharmacodynamics of artemether-lumefantrine treatment.

149 safety, tolerability, pharmacokinetics, and pharmacodynamics of avoralstat.

150 iminary activity, pharmacokinetics (PK), and pharmacodynamics of BKM120, a potent and highly specific

151 med to characterize the pharmacokinetics and pharmacodynamics of BMS-184474.

152 The pharmacodynamics of bortezomib were evaluated by measure

153 -tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of carfilzomib administered as a 30-min

154 ctionation study to characterize the in vivo pharmacodynamics of CAS activity during IPA, using immun

155 A paucity of data exists regarding the pharmacodynamics of caspofungin (CAS) during invasive pu

156 Here, we characterize the efficacy and pharmacodynamics of CFTR(inh)-172 in blocking cAMP and c

157 The influence of these transporters on the pharmacodynamics of cisplatin, carboplatin, and oxalipla

158 assess the toxicities, pharmacokinetics, and pharmacodynamics of cixutumumab in children to determine

159 zed, placebo-controlled trial evaluating the pharmacodynamics of clopidogrel in children (0 to 24 mon

160 or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants:

161 Is) on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel.

162 he purpose of this study was to document the pharmacodynamics of CO2 for MBF using prospective end-ti

163 gnificant impact on the pharmacokinetics and pharmacodynamics of CPT-11.

164 safety, tolerability, pharmacokinetics, and pharmacodynamics of CSL112 in patients with a recent acu

165 The pharmacodynamics of Cyto-012 and wt BoNT/A have similar

166 safety, tolerability, pharmacokinetics, and pharmacodynamics of deforolimus (previously known as AP2

167 is of the antiviral effects, toxicities, and pharmacodynamics of different variants of cardiac glycos

168 irst article describing the pharmacokinetics/pharmacodynamics of doripenem solely in critically ill p

169 has indicated that the pharmacokinetics and pharmacodynamics of DrotAA are similar in children and a

170 udies that describe the pharmacokinetics and pharmacodynamics of drugs in pregnant women are critical

171 velop an experimental system to evaluate the pharmacodynamics of dual phage-drug therapy.

172 aluated, as well as the pharmacokinetics and pharmacodynamics of ENB-0040.

173 designed to assess safety, tolerability, and pharmacodynamics of FBS0701, a novel oral chelator, in a

174 We characterized the mechanism and pharmacodynamics of five structurally distinct inhibitor

175 clearance, alters both pharmacokinetics and pharmacodynamics of furosemide in acute kidney injury, a

176 safety, tolerability, pharmacokinetics, and pharmacodynamics of GP2013 plus cyclophosphamide, vincri

177 rapeutic applications aimed at improving the pharmacodynamics of heparin in the treatment of AHR and

178 udies investigating the pharmacokinetics and pharmacodynamics of high-dose IVMP need to be performed

179 the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-cl

180 ose (MTD), toxicities, pharmacokinetics, and pharmacodynamics of imexon in patients with advanced can

181 The pharmacodynamics of inhaled heparin are however transien

182 e assessed the safety, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx, a second-generation a

183 to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children aged 2-5 years

184 oxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of ixabepilone when administered as a 1

185 ed dose (MTD), safety, pharmacokinetics, and pharmacodynamics of LCL161 in patients with advanced sol

186 g analysis was done to better understand the pharmacodynamics of Lithium by isolating the norepinephr

187 The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the mos

188 We studied the pharmacokinetics and pharmacodynamics of micafungin in a rabbit model of neon

189 ercellular drug transfer that contributes to pharmacodynamics of neighboring cells.

190 suggest that prior stress can influence the pharmacodynamics of opiates that are used in clinical se

191 idine deaminase, on the pharmacokinetics and pharmacodynamics of oral DAC were evaluated in mice and

192 dy was undertaken to define the efficacy and pharmacodynamics of R115777, a farnesyl transferase inhi

193 roteins involved in the pharmacokinetics and pharmacodynamics of rasagiline, and genes previously ass

194 safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human LCAT (ACP-501).

195 significantly improved pharmacokinetics and pharmacodynamics of repeated mATG administration.

196 ndary outcomes were the pharmacokinetics and pharmacodynamics of ricolinostat in this combination and

197 dy reports the safety, pharmacokinetics, and pharmacodynamics of RTX in patients with end-stage renal

198 ics of ligand-induced IKK activation and the pharmacodynamics of selective inhibitors of both IKK and

199 acterize the toxicity, pharmacokinetics, and pharmacodynamics of selinexor, a selective inhibitor of

200 taken by analysing the pharmacokinetics and pharmacodynamics of single doses of subcutaneous aldesle

201 This study evaluated the safety and pharmacodynamics of single, intravenous doses (0.025, 0.

202 phoramidates could be important for improved pharmacodynamics of telomerase inhibitors in cancer ther

203 models incorporate the pharmacokinetics and pharmacodynamics of the antibiotics, the innate and adap

204 ed dose (MTD), safety, pharmacokinetics, and pharmacodynamics of the combination in patients with ref

205 d to reflect pharmacological action and thus pharmacodynamics of the delivered enzyme.

206 nteractions and altered pharmacokinetics and pharmacodynamics of the different antihypertensive medic

207 pairs motor performance concomitant with the pharmacodynamics of the drug, but also impairs future mo

208 te understanding of the pharmacokinetics and pharmacodynamics of the drugs.

209 We review the pharmacokinetics and pharmacodynamics of the pediatric procedural sedation ph

210 We assessed the safety and pharmacodynamics of the vaccine in patients with coeliac

211 emporal tissue pharmacokinetics and in vitro pharmacodynamics of these FQs.

212 ient differences in the pharmacokinetics and pharmacodynamics of these medications.

213 The pharmacokinetics and pharmacodynamics of ticagrelor 60 mg bid have not been s

214 This study compares the pharmacokinetics and pharmacodynamics of tipifarnib at MTD in patients on and

215 -tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of tipifarnib in children with refracto

216 mulations and to characterize the safety and pharmacodynamics of triamcinolone acetonide (TA) deliver

217 med to characterize the pharmacokinetics and pharmacodynamics of troxacitabine.

218 o evaluate the safety, pharmacokinetics, and pharmacodynamics of VEGF Trap administered intravenously

219 The pharmacodynamics of voriconazole against wild-type and 3

220 ought to explore the activity, toxicity, and pharmacodynamics of ZD1839 in SCCHN.

221 harmacokinetics) and the biological effects (pharmacodynamics) of the chemical on the organism.

222 integration of biomarkers reporting on drug pharmacodynamics or on a disease state is becoming neces

223 Pharmacodynamics outcomes were modeled using a Bayesian

224 of different genetic variants on clopidogrel pharmacodynamics over time in patients undergoing PCI.

225 e used to assess furosemide pharmacokinetics/pharmacodynamics parameters.

226 armacokinetics of GS-9620, and the following pharmacodynamics parameters: interferon-stimulated gene

227 ween plasma pharmacokinetics (PK), tumor PK, pharmacodynamics (PD) (client protein degradation), tumo

228 survival, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of 2,4-[[(3,5-dimethylanilino)carb

229 stemic and mucosal pharmacokinetics (PK) and pharmacodynamics (PD) of 2F5 IgG and 2F5 Fab fragments w

230 ffect of smoking on the pharmacokinetics and pharmacodynamics (PD) of clopidogrel and prasugrel thera

231 se as a whole, and evaluated the single-cell pharmacodynamics (PD) of Ptx (by in vivo PD microscopy).

232 ty, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of rontalizumab, a humanized IgG1

233 apecitabine on the pharmacokinetics (PK) and pharmacodynamics (PD) of warfarin.

234 itiating hydroxyurea therapy, to investigate pharmacodynamics (PD) parameters, including HbF response

235 ET and assess the pharmacokinetics (PK) and pharmacodynamics (PD) profile of OA.

236 ety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-0056

237 safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of KRN23 follo

238 An understanding of pharmacokinetics (PK), pharmacodynamics (PD), antimicrobial susceptibility test

239 imum tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of duvelisib

240 cogenetics, including pharmacokinetics (PK), pharmacodynamics (PD), gene and pathway interactions, an

241 genes involved in pharmacokinetics (PK) and pharmacodynamics (PD).

242 ion affecting drug pharmacokinetics (PK) and pharmacodynamics (PD).

243 bes synthesis and stereospecific comparative pharmacodynamics (PD, anticonvulsant activity and terato

244 usceptibility to an antibacterial agent (ie, pharmacodynamics [PD]), is a given; however, drug exposu

245 rmacokinetics [PK]) and protective efficacy (pharmacodynamics [PD]).

246 This article also reviews the pharmacodynamics, pharmacokinetics, and drug interaction

247 tment and follow-up and were included in the pharmacodynamics, pharmacokinetics, and safety analyses.

248 The study assessed the pharmacodynamics, pharmacokinetics, and safety of BMS-66

249 the three major pillars of drug development-pharmacodynamics, pharmacokinetics, and toxicity studies

250 We assessed the pharmacodynamics, pharmacokinetics, preliminary efficacy

251 We discuss the pharmacodynamics, pharmacokinetics, toxic effects, and c

252 Here we use pharmacokinetics/pharmacodynamics (PK/PD) analysis to rationally develop

253 -TB) is designed to perform pharmacokinetics/pharmacodynamics (PK/PD) experiments, and hence the desi

254 arge number of tuberculosis pharmacokinetics/pharmacodynamics (PK/PD) studies that have not been subj

255 on was driven by a modified pharmacokinetics-pharmacodynamics (PK/PD)-based dosing approach.

256 001, using the index terms pharmacokinetics, pharmacodynamics, plasminogen activator, reteplase, lano

257 idered, including viral pharmacokinetics and pharmacodynamics, potential toxic effects, and monitorin

258 In addition, pharmacokinetics/pharmacodynamics profile in serum and lung tissue showed

259 sign of covalent inhibitors with appropriate pharmacodynamics properties coupled with limited unwante

260 ay, in part, be parkin-independent or to the pharmacodynamics properties of nilotinib.

261 tically characterize the pharmacokinetic and pharmacodynamics properties of the SMN splicing modifier

262 lyglutamine-expanded proteins as well as the pharmacodynamics readouts to monitor their efficacy in p

263 tered pharmacokinetics (p < 0.01), a reduced pharmacodynamics response to furosemide also became impo

264 aluation Criteria in Solid Tumors) response, pharmacodynamics, RET mutational status, and biomarker a

265 We evaluated the pharmacokinetics (PKs), pharmacodynamics, safety, and efficacy of selinexor, an

266 l evaluation of ETX0914 pharmacokinetics and pharmacodynamics showed distribution into vascular tissu

267 are not a unidirectional influence on opioid pharmacodynamics, since TLR4(-/-) mice had reduced oxyco

268 Human pharmacokinetics/pharmacodynamics studies confirmed this link between mic

269 al evolution in patients on optimal therapy, pharmacodynamics studies explaining the extraordinarily

270 ry-based timolol release studies and in vivo pharmacodynamics studies in beagle dogs to evaluate the

271 tigation of kinetic mechanisms in disease or pharmacodynamics studies using MS data from longitudinal

272 cokinetic analyses, in vivo pharmacokinetics/pharmacodynamics studies, and maximum-tolerated-dose stu

273 ive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the impact of vancomy

274 rated cellular PTX pharmacokinetics with PTX pharmacodynamics successfully predicted effects of exoso

275 eflect the functional effects of a drug--its pharmacodynamics, such as vasoconstriction.

276 Pharmacodynamics suggested that a single dose of oritava

277 physical function, frailty, disability, and pharmacodynamics that all merit further investigation.

278 w previously unappreciated complex nonlinear pharmacodynamics that determine their inhibitory potenti

279 of fMRI affords detailed mapping of regional pharmacodynamics that underlie mechanisms of pain suppre

280 orating viral dynamics and pharmacokinetics/ pharmacodynamics to assess how suboptimal adherence affe

281 ing of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneou

282 h vein injection, and exhibited the expected pharmacodynamics to remove uric acid in hyperuricemic bl

283 This study evaluated the pharmacokinetics, pharmacodynamics, tolerability, safety, and efficacy of

284 e processes, analytical tools for population pharmacodynamics, tools for the analysis of genomic expr

285 -miR, which is more robust than conventional pharmacodynamics using downstream target gene derepressi

286 formulation is a major factor in optimizing pharmacodynamics using this technique.

287 Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite rigorous exclusion

288 Combining models of drug pharmacokinetics, pharmacodynamics, viral kinetics and symptom dynamics, w

289 Pharmacodynamics were assessed by measuring the ability

290 Pharmacokinetics and pharmacodynamics were assessed on days 9 and 10.

291 Pharmacokinetics and pharmacodynamics were assessed.

292 Plasma pharmacodynamics were evaluated for both 1- and 3-hour i

293 Pharmacokinetics, immunogenicity, and pharmacodynamics were evaluated, and disease activity wa

294 ures and pharmacokinetics were assessed, and pharmacodynamics were measured in blood, hair follicles,

295 Efficacy and pharmacodynamics were secondary end points.

296 Etoposide pharmacokinetics and pharmacodynamics were studied for 47, 28, and 26 patient

297 tify a peptide with improved tumor-to-kidney pharmacodynamics when compared with current candidates.

298 nt altered indomethacin pharmacokinetics and pharmacodynamics, which is probably the result of reduce

299 the RTB carrier may support distinct in vivo pharmacodynamics with potential to address hard-to-treat

300 edisposition to altered pharmacokinetics and pharmacodynamics with resulting increased risk of toxici